Jean Michel Halfon

Board Director

Director

US·SEC (Form 4)

Teva Pharmaceutical Industries Ltd

Total declarations

Company

▲ Purchases (0 ops.)

—

▼ Sales (0 ops.)

—

Latest filing published 16 Jun 2022 for Teva Pharmaceutical Industries Ltd. Read the official filing

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

Jean Michel Halfon: trading record in brief

Jean Michel Halfon (board member) discloses dealings in Teva Pharmaceutical Industries Ltd to SEC (Form 4). Between 5 June 2021 and 14 June 2022, the trades on record add up to 3 filings.

No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.

The latest filing, published on 16 June 2022, reports an option exercise in Teva Pharmaceutical Industries Ltd. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.